Okeiro (previously often called Predict4Health), a Paris, France-based firm specializing in precision drugs for transplantation and superior persistent ailments, raised €10m in funding.
The spherical was led by Alven, Forepont Capital Companions and Pink River West.
The corporate intends to make use of the funds to speed up its deployment in France and internationally. A part of the funds will even be used to develop new AI instruments to additional enhance the precision of diagnostics, therapeutic suggestions, and acceleration of scientific analysis in end-stage persistent illness and transplant sufferers.
Led by Pierrick Arnal, CEO, Okeiro is pioneering a complicated scientific choice assist platform that leverages synthetic intelligence to forestall organ failure (kidneys, lungs, coronary heart, and liver).
On the core of the platform is the iBox algorithm—a clinically validated predictive mannequin, marked as a medical gadget and certified as a surrogate endpoint by FDA and EMA—developed in collaboration with their strategic analysis accomplice at APHP and INSERM, France’s premier medical analysis establishment. This proprietary expertise permits physicians to establish post-transplant issues, revolutionizing affected person monitoring and therapy protocols and accelerating scientific trials timelines.
Already carried out in transplant facilities throughout France and benefiting hundreds of sufferers, the platform has achieved nationwide reimbursement standing by the French Nationwide Well being Insurance coverage, validating each its scientific utility and financial worth inside established distant monitoring frameworks.
Okeiro is at the moment conducting a randomized scientific trial throughout 16 hospital facilities in 6 international locations (France, Germany, United Kingdom, Austria, Israel, Spain). The target is to show the effectiveness of its expertise by evaluating outcomes between physicians utilizing the platform and a gaggle of physicians making use of normal care protocols. Interim outcomes are very constructive, and the research will likely be accomplished inside a couple of months.
FinSMEs
11/04/2025
